# Zamtocabtagene autoleucel

Source: https://onco.cc/drugs/zamtocabtagene-autoleucel/  
OnCo record `zamtocabtagene-autoleucel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zamtocabtagene autoleucel is an experimental CAR-T cell therapy from Miltenyi Biomedicine in phase 2 trials for diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma, aimed at CD19 and CD20.

## Summary

Zamtocabtagene autoleucel (CART2019) is a CAR-T cell therapy developed by Miltenyi Biomedicine. Its targets are CD19 and CD20 (the sponsor names CD19-CD20). The sponsor states: tandem CAR-T approach targeting two B-cell antigens. ClinicalTrials.gov describes the intervention as: Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in diffuse large B-cell lymphoma, primary CNS lymphoma and mantle cell lymphoma. The largest, NCT04792489, plans to enrol 315 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: zamtocabtagene autoleucel (MB-CART2019.1)
- Tags: pipeline; ctgov-ingest
- Code: CART2019
- Modality: CAR-T cell therapy
- Mechanism: tandem CAR-T approach targeting two B-cell antigens.

## Sources

- ClinicalTrials.gov: trials of Zamtocabtagene autoleucel: https://clinicaltrials.gov/search?intr=CART2019
- Sponsor page: https://www.miltenyibiomedicine.com

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Primary CNS lymphoma](https://onco.cc/cancers/primary-cns-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/)
- companies: [Miltenyi Biomedicine](https://onco.cc/companies/miltenyi-biomedicine/)
- trials: [DALY II Japan/MB-CART2019.1 for DLBCL](https://onco.cc/trials/nct07288879/), [DALY II USA/ MB-CART2019.1 for DLBCL](https://onco.cc/trials/nct04792489/), [Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients](https://onco.cc/trials/nct04844866/), [Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms](https://onco.cc/trials/nct06508931/)

---
JSON: https://onco.cc/api/v1/entities/zamtocabtagene-autoleucel.json